CBLB and gastric cancer: β-Elemicene can inhibit the peritoneal metastasis of gastric cancer by inhibiting FAK activation, as well as reverse multidrug chemoresistance by modulating the miR-1323/Cbl-b/EGFR pathway, in addition to sensitizing chemotherapeutic agents [39, 40].